基于多维度临床数据整合分析揭示SLC25A12表达水平在急性髓系白血病患者中的预后价值  

Prognostic Value of SLC25A12 Expression in Patients with Acute Myeloid Leukemia Based on Integrated Analysis of Multi-dimensional Clinical Data

作　　者：刘宇辰 尹成亮 陈奇 陈晶[1] 马彦青 王莉莉[1] 刘代红[1] 石金龙[3] 窦立萍[1] LIU Yu-Chen;YIN Cheng-Liang;CHEN Qi;CHEN Jing;MA Yan-Qing;WANG Li-Li;LIU Dai-Hong;SHI Jin-Long;DOU Li-Ping(Department of Hematology,Chinese PLA General Hospital,Beijing 100853,China;The Hospital of PLA Unit 66058,Tianjin301799,China;Medical Big Data Center,Chinese PLA General Hospital,Beijing 100853,China)

机构地区：[1]中国人民解放军总医院血液科,北京100853 [2]中国人民解放军66058部队医院,天津301799 [3]中国人民解放军总医院医学大数据中心,北京100853

出　　处：《中国实验血液学杂志》2020年第2期377-384,共8页Journal of Experimental Hematology

基　　金：北京市科技新星计划(2011114);国家自然科学基金(81770203,30971297,81102242,81000221,81270610,81470010,81170518,81370666,90919044);北京市自然科学基金(7102147,7172200,7132217);首都卫生发展科研专项项目(首发2016-1-4082);海南省自然科学基金(818MS157).

摘　　要：目的:研究分析SLC25A12在急性髓系白血病(AML)患者中的临床和预后价值。方法:本研究分别在2个队列中(n=46;n=290)比较了SLC25A12基因在AML患者和健康人骨髓或外周血细胞中的表达水平,利用2个独立AML研究队列(n=163;n=329)的基因组、转录组、临床和预后等多维度信息进行整合,分析SLC25A12的预后价值。结果:在AML患者白血病细胞中,SLC25A12的表达量明显高于健康人(P=0.0001;P=0.0238),单因素和多因素预后分析证实,SLC25A12高表达与患者较短的无事件生存(EFS,HR=1.605,P=0.018)和总体生存(OS,HR=1.818,P=0.002)显著相关。这进一步证实在预后危险度为预后良好和预后中等两个亚组中,SLC25A12高表达的患者无事件生存和总体生存同样显著降低。结论:SLC25A12高表达与AML患者的不良预后生存显著相关,这提示SLC25A12异常表达可作为AML预后评估的潜在的分子标志物。Objective:To investigate the clinical and prognostic value of SLC25 A12 in patients with acute myeloid leukemia(AML).Methods:The expression levels of SLC25 A12 in bone marrow or peripheral blood cells of AML patients and healthy people in two independent cohorts(n=46,n=290,respectively)were compared.Then it was assessed that the prognostic value of SLC25 A12 expression in two independent AML study cohorts(n=163,n=329,respectively)by mean of integrated analysis of genomic,transcriptome,clinical and prognosis information.Results:The expression of SLC25 A12 in AML patients significantly increased as compared with that of healthy people(P=0.0001,P=0.0238,respectively).Univariate and multivariate analyze showed that high SLC25 A12 expression was significantly associated with shorter event-free survival(EFS)(HR=1.605,P=0.018)and overall survival(OS)(HR=1.818,P=0.002)of patients.In favorable-risk and intermediate-risk subgroups,patients with high SLC25 A12 expression showed shorter EFS and OS than patients with low SLC25 A12 expression.Conclusion:High SLC25 A12 expression significantly associated with poor prognosis of AML patients,which suggests that SLC25 A12 aberrant expression can be used as a potential molecular marker for prognosis evaluation of AML patients.

关 键 词：急性髓系白血病 SLC25A12 预后 

分 类 号：R733.71[医药卫生—肿瘤]